NCT00445484View on ClinicalTrials.gov

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2007

Primary Completion Date

April 30, 2009

Study Completion Date

September 30, 2010

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
BIOLOGICAL

pneumococcal polyvalent vaccine

Given intramuscularly

DRUG

lenalidomide

Given orally

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00445484 - Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter